MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Gossamer Bio, Inc. (Nasdaq: GOSS)*
Organization & Developments: Gossamer
Parents
Gossamer Bio, Inc. (Nasdaq: GOSS)*
Children
*A clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology
2019: Gossamer_This Biotech Just Gave Up A Breakout — Why An Analyst Is Still Bullish_www.investors.com
2021: Gossamer Bio: Circling Back After A Rebound Off Lows
2021: Taking A Gander At Gossamer Bio
2022: Announced that Phase 2 SHIFT-UC clinical trial of GB004 in mild-to-moderate active ulcerative colitis didn't meet its primary or secondary objectives at week 12
2022: Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise_ seekingalpha.com
2023: Gossamer lays off 25% of employees, cuts all programs except PAH drug
2023: Two patient deaths lead to FDA partial hold for Gossamer trial of lymphoma drug
2025: Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
2025: Gossamer Bio: A Critical Year Ahead
2026: What to expect from Gossamer Bio's late-stage lung disease study
Jumps
Finance & Acquisitions: Gossamer
Key People: Gossamer